EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Klinische Studie (Phase II)Open Access · CC BY 4.0

Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults

Jaya Goswami, Abdullah H Baqui, Pablo A Doreski, Gonzalo Perez Marc, Gilberto Jimenez, Salahuddin Ahmed, Khalequz Zaman, Christopher J A Duncan, Mugen Ujiie iD, Mika Rämet, Lina Pérez-Breva, Lan Lan und 15 weitere

The Journal of Infectious Diseases · 15.11.2024 · 230 (5) · e996-e1006

DOI: 10.1093/infdis/jiae316 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 18.06.2024. Verfasst von Jaya Goswami und 26 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease, Research and Development, Moderna, Inc., Cambridge, Massachusetts. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial virus (RSV) disease with acceptable safety in adults aged ≥60 years in the ConquerRSV trial. Here, humoral immunogenicity results from the trial are presented.

Methods

This phase 2/3 trial randomly assigned adults (≥60 years) to mRNA-1345 50-µg encoding prefusion F (preF) glycoprotein (n = 17 793) vaccine or placebo (n = 17 748). RSV-A and RSV-B neutralizing antibody (nAb) and preF binding antibody (bAb) levels at baseline and day 29 postvaccination were assessed in a per-protocol immunogenicity subset (PPIS; mRNA-1345, n = 1515; placebo, n = 333).

Results

Day 29 nAb geometric mean titers (GMTs) increased 8.4-fold against RSV-A and 5.1-fold against RSV-B from baseline. Seroresponses (4-fold rise from baseline) in the mRNA-1345 groups were 74.2% and 56.5% for RSV-A and RSV-B, respectively. Baseline GMTs were lower among participants who met the seroresponse criteria than those who did not. mRNA-1345 induced preF bAbs at day 29, with a pattern similar to nAbs. Day 29 antibody responses across demographic and risk subgroups were generally consistent with the overall PPIS. Conclusions mRNA-1345 enhanced RSV-A and RSV-B nAbs and preF bAbs in adults (≥60 years) across various subgroups, including those at risk for severe disease, consistent with its demonstrated efficacy in the prevention of RSV disease. Clinical Trials Registration NCT05127434.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsAntibodies, ViralAntibodies, NeutralizingRespiratory Syncytial Virus, HumanHumansMaleFemaleAgedMiddle AgedAged, 80 and overImmunogenicity, VaccineImmunity, HumoralDouble-Blind MethodmRNA Vaccines

Stichwörter der Autor:innen

RSVbinding antibodyimmunogenicitymRNA-1345neutralizing antibody

Substanzen

Respiratory Syncytial Virus VaccinesAntibodies, ViralAntibodies, NeutralizingmRNA-1345 respiratory syncytial virus vaccinemRNA Vaccines

Autor:innen und Institutionen

  • Infectious Disease, Research and Development, Moderna, Inc., Cambridge, Massachusetts.
  • Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich.
  • Consultorios Médicos Dr. Doreski, Buenos Aires, Argentina.
  • Spotlight Research Center, Miami, Florida.
  • Department of International Health, Johns Hopkins University, Zakiganj, Sylhet, Bangladesh.

ORCID-Profile: Mugen Ujiie

Förderung

  • Moderna, Inc

Zitieren

APA

Goswami, J., Baqui, A. H., Doreski, P. A., Perez Marc, G., Jimenez, G., Ahmed, S., Zaman, K., Duncan, C. J. A., Ujiie, M., Rämet, M., Pérez-Breva, L., Lan, L., Du, J., Kapoor, A., Mehta, S., Tomassini, J. E., Huang, W., Zhou, H., Stoszek, S. K., …, & Das, R. (2024). Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults. The Journal of Infectious Diseases, 230(5), e996-e1006. https://doi.org/10.1093/infdis/jiae316

Vancouver

Goswami J, Baqui AH, Doreski PA, Perez Marc G, Jimenez G, Ahmed S, et al. Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults. The Journal of Infectious Diseases. 2024;230(5):e996-e1006. doi:10.1093/infdis/jiae316

BibTeX
@article{Goswami2024,
  author = {Goswami, Jaya and Baqui, Abdullah H and Doreski, Pablo A and Perez Marc, Gonzalo and Jimenez, Gilberto and Ahmed, Salahuddin and Zaman, Khalequz and Duncan, Christopher J A and Ujiie, Mugen and Rämet, Mika and Pérez-Breva, Lina and Lan, Lan and Du, Jiejun and Kapoor, Archana and Mehta, Shraddah and Tomassini, Joanne E and Huang, Wenmei and Zhou, Honghong and Stoszek, Sonia K and Priddy, Frances and Lin, Nina and Le Cam, Nancy and Shaw, Christine A and Slobod, Karen and Wilson, Eleanor and Miller, Jacqueline M and Das, Rituparna},
  title = {Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {230},
  number = {5},
  pages = {e996--e1006},
  doi = {10.1093/infdis/jiae316}
}
Kostenlos starten →